Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
 
 
First Trust NYSE Arca Biotechnology Index Fund (FBT)
Investment Objective/Strategy - The First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology IndexSM.
There can be no assurance that the Fund's investment objectives will be achieved.
  • The NYSE Arca Biotechnology IndexSM is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
  • Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.
  • The index is rebalanced quarterly based upon closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent an approximately equal weight in the index.
Fund Overview
TickerFBT
Fund TypeBiotechnology
Investment AdvisorFirst Trust Advisors L.P.
Investor Servicing AgentBank of New York Mellon
CUSIP33733E203
ISINUS33733E2037
Intraday NAVFBTIV
Fiscal Year-End12/31
ExchangeNYSE Arca
Inception6/19/2006
Inception Price$20.00
Inception NAV$20.00
Rebalance FrequencyQuarterly
Gross Expense Ratio*0.55%
Net Expense Ratio*0.55%
* As of 5/3/2021
Expenses are capped contractually at 0.60% per year, at least until April 30, 2022.
Current Fund Data (as of 6/22/2021)
Closing NAV1$173.52
Closing Market Price2$173.47
Bid/Ask Midpoint$173.54
Bid/Ask Premium0.01%
30-Day Median Bid/Ask Spread30.07%
Total Net Assets$1,969,443,426
Outstanding Shares11,350,002
Daily Volume51,778
Average 30-Day Daily Volume49,705
Closing Market Price 52-Week High/Low$184.84 / $150.39
Closing NAV 52-Week High/Low$184.97 / $150.28
Number of Holdings (excluding cash)30
NAV History (Since Inception)
Past performance is not indicative of future results.
Fund Characteristics (as of 5/28/2021)4
Maximum Market Cap.$136,709
Median Market Cap.$16,277
Minimum Market Cap.$1,958
Price/Book4.61
Price/Sales6.91
Top Holdings (as of 6/22/2021)*
Holding Percent
FibroGen, Inc. 4.33%
Biogen Inc. 4.32%
Moderna, Inc. 4.04%
Alnylam Pharmaceuticals, Inc. 3.88%
Alkermes Plc 3.80%
ACADIA Pharmaceuticals Inc. 3.67%
Illumina, Inc. 3.64%
bluebird bio, Inc. 3.61%
IQVIA Holdings Inc. 3.53%
Charles River Laboratories International, Inc. 3.50%

* Excluding cash.  Holdings are subject to change.

Bid/Ask Premium/Discount (as of 6/22/2021)
  2020 Q1 2021 Q2 2021 Q3 2021
Days Traded at Premium 96 32 29 ---
Days Traded at Discount 157 29 28 ---
Hypothetical Growth of $10,000 Since Inception (as of 6/22/2021) *